For 12 Weeks, the Multi Center, Randomized, Double Blinded, Placebo Controlled, Parallel, Dose-finding Clinical Study for the Therapeutic Exploration of Safety and Efficacy Assessment of HL237 Tablet in Patients With Rheumatoid Arthritis (Phase IIa)
Latest Information Update: 07 Nov 2022
At a glance
- Drugs HL-237 (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors Hanlim Pharmaceutical
Most Recent Events
- 26 Nov 2020 New trial record